GSK:NYSEGSK plc Analysis

GSK trades at $56.37, well above its DCF‑derived fair value of $21.59, indicating a significant premium. The stock’s PE of 15.36 is comfortably below the industry average of 25.57, and its forward PE of 10.98 suggests earnings growth expectations are baked in. A dividend yield of 3.15% with a payout ratio under 50% (46.5%) and strong free cash flow ($3.28 bn) support the sustainability of the payout. Fundamentals are robust: revenue grew 6.2% YoY to $32.7 bn, gross margin sits at 72.6%, and ROE is an impressive 43.3%. However, the balance sheet is leveraged, with a debt‑to‑equity of 111.5, though cash generation remains ample.
Technical indicators show a bullish MACD histogram (+0.43) and RSI at 58, placing the price above the 20‑day SMA ($54.15) and near the 50‑day SMA ($55.63) but still below the near‑term resistance of $57.18. Volume is stable and beta is low (0.31), implying limited price swings relative to the market, while 30‑day volatility of 24% is moderate for the sector. Analyst consensus is a “hold” with a median price target of $56, aligning closely with the current price, suggesting limited upside in the short run but potential upside if growth catalysts materialize.